0000950170-24-053000.txt : 20240503 0000950170-24-053000.hdr.sgml : 20240503 20240503164649 ACCESSION NUMBER: 0000950170-24-053000 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240501 FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DICICCO WENDY F CENTRAL INDEX KEY: 0001225165 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36288 FILM NUMBER: 24913999 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akari Therapeutics Plc CENTRAL INDEX KEY: 0001541157 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981034922 STATE OF INCORPORATION: X0 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF ROAD STREET 2: FL 7 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (646) 350-0702 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF ROAD STREET 2: FL 7 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Celsus Therapeutics Plc. DATE OF NAME CHANGE: 20130621 FORMER COMPANY: FORMER CONFORMED NAME: Morria Biopharmaceuticals PLC DATE OF NAME CHANGE: 20120201 4 1 ownership.xml 4 X0508 4 2024-05-01 0001541157 Akari Therapeutics Plc AKTX 0001225165 DICICCO WENDY F C/O AKARI THERAPEUTICS, PLC 22 BOSTON WHARF ROAD FL 7 BOSTON MA 02210 false true false false Interim CFO false Ordinary Shares, par value $0.0001 per share 2024-05-01 4 A false 158473915 0.00 A 158473915 D These shares represent restricted stock units ("RSUs") granted under the Issuer's 2023 Equity Incentive Plan, with each such RSU representing the right to receive one ordinary share, par value $0.0001. One-hundered percent (100%) of the RSUs shall vest on May 1, 2025 (first anniversary of the date of grant), subject to the Reporting Person's continued service with the Issuer on the vesting date. Notwithstanding the foregoing, should the Issuer terminate the Reporting Person for any reason other than for cause prior to the vesting date, the RSUs will continue to vest through the first anniversary of the date of grant or be accelerated, at the Issuer's option. /s/ Wendy F. DiCicco 2024-05-03